ADHD Therapeutics Market

ADHD Therapeutics Market Size (2023 to 2028)

The global ADHD therapeutics market is anticipated to reach USD 49.82 billion by 2028 from USD 32.24 billion in 2023. The market is expected to grow at a CAGR of 9.09% during the forecast period. 

ADHD Therapeutics Market Share Insights:

• Based on treatment on medication, the stimulants segment had the leading share of the global market in 2022.
• Based on treatment by psychotherapy, the behavior therapy segment held the major share of the worldwide market in 2022.
• North America accounted for 36% of the worldwide market share in 2022.

Attention deficit hyperactivity disorder (ADHD) is a neurodevelopmental disorder that damages and envelops symptoms of impulsivity and hyperactivity. Treating and controlling the disease with the help of technology defines neurobehavioral because of how the brain affects learning, behavior, and emotion. Patients with this disorder suffer from a lack of concentration at work and in life. The problem may stem from childhood and grow into adulthood for several people. Having ADHD can lead to problems in a person's personal and professional life and may lead to low self-esteem and sometimes anxiety and depression. ADHD can stop an individual from exploring their full potential, and the treatment for the problem often includes drugs and talk therapy. ADHD therapeutics work on boosting the chemicals in the brain that promote focus and reduce hyperactivity to help the patients focus better. In addition, several psychological therapies help improve the attention span of these patients and may help them stabilize their condition for life. 

Impact of COVID-19 on the global ADHD therapeutics market:

COVID-19 has boosted the growth rate of the global ADHD therapeutics market. COVID-19 has had a lot of negative impacts on people suffering from attention-deficit hyperactivity disorder. The main reason for the effect is vulnerability to the distress caused by the pandemic and physical distancing measures. Due to these factors, the patient can showcase increased behavioral problems. The increase in the issues will boost the sale of ADHD therapeutics, and the panic buying by consumers has finished stock of the current batch of medicines and forced them to make a new batch. In addition, hospital visits for non-essential medical conditions have been postponed, causing individuals with ADHD to rely solely on drugs.

Furthermore, the growing cases of loneliness and depression due to the lack of social interactions have led to more severe ADHD problems. Patients also suffered in managing time while working and studying from a home-based setting. The growing awareness regarding the need for ADHD medication led to profuse for the market. However, the lack of availability of proper psychiatric help due to restrictions in healthcare settings led to a drawback for the market. Therefore, the pandemic had a mixed impact on the ADHD therapeutics market. 

MARKET DRIVERS:

The growing incidence of attention deficit hyperactivity disorder across the world propels the global ADHD therapeutics market growth.

The causes of ADHD are still indistinct, although genetic presence is observed in many cases. As per the data given by the Centre for Disease Control and Prevention (CDC) in 2016, around 6.1 million individuals, including 388,000 children aged 2–5 years, 4 million 6–11 years, and 3 million 12–17 years, were diagnosed with ADHD in the U.S. besides, boys are more likely to be diagnosed than girls. There has been an increase in the diagnosis of ADHD due to the growing awareness regarding the condition and the rising number of people seeking healthcare for mental health. Additionally, in recent years there has been more light on the fact that ADHD can also be witnessed in adults and is quite common, as it was previously thought to be a purely child-related disorder.  

The frequency of ADHD is rising at a higher rate, which drives the global attention-deficit hyperactivity disorder therapeutics market, as there is no treatment for this disorder. Furthermore, the ADHD therapeutics market is driven by the rough impact of unstable lifestyles and additives in children's diets, increasing the incidence of ADHD within the 4-to-17-year age group. Moreover, increasing awareness concerning the syndrome among physicians and patients and opinion-based due to the lack of regular diagnostic tests is anticipated to fuel the growth of the worldwide ADHD market in the coming future.  

Additionally, increasing advancements in the medical field, a growing number of research in neurosciences, and raising awareness about mental illness among people are fuelling the market growth to a considerable extent. Furthermore, expanding the focus of biotechnology & pharmaceutical companies into developing innovative therapeutics for ADHD drives the development of the global ADHD therapeutics market. The rising research in the field of new therapies supports market growth. For example, the new FDA-approved ADHD device, Monarch external Trigeminal Nerve Stimulation (eTNS) System, releases minute electric pulses in the brain, significantly reducing inattentiveness. Endeavor Rx is a digital video game made as a therapy for ADHD, and it won the approval of the FDA in 2020. In addition, an experimental non-stimulant drug by the name SPN-812 (viloxazine extended-release) made headlines in 2020 and was also published in the journal of clinical therapeutics.

MARKET RESTRAINTS:

The high cost of ADHD medications, improper reimbursement policies, and side effects related to ADHD medications (such as insomnia, anorexia, dizziness, headaches, and mood changes) are restraining the growth of the global ADHD therapeutics market. In addition, all the side effects associated with ADHD drugs affect the patients' lives and hamper the revenue growth of the attention-deficit hyperactivity disorder therapeutics market in the forecast period. In addition, problems like allergic reactions to medicine and medical conditions like coronary artery disease, kidney disease, and seizures are associated with attention deficit hyperactivity disorder medicines.

This research report on the global attention deficit hyperactivity disorder therapeutics market has been segmented and sub-segmented based on the type, production technologies, and region. 

ADHD Therapeutics Market - Treatment by Medication:

• Stimulants
  • Amphetamines 
  • Methylphenidate    
  • Dextroamphetamine   
  • Dexmethylphenidate  
• Non-Stimulants
  • Atomoxetine   
  • Bupropion    
  • Guanfacine   

Based on the medication types, the stimulants segment is estimated to hold a major share of the worldwide market during the forecast period and is expected to grow at a promising rate from 2022 to 2027. Stimulants are expected to emerge as the drugs of choice among physicians and patients worldwide. Amphetamine is also predicted to gain popularity over the forecast period. Around 70-80% of children who have ADHD use stimulants as medication to treat the disease. These stimulants help cure ADHD. In addition, these drugs act as a stimulant for the central nervous system. The most common stimulant used is Concerta (methylphenidate), Dexedrine (amphetamine), and Evekeo (amphetamine).

The Non-stimulants segment accounted for the second largest market share in 2021, and with the rise in cases, the growth is expected to be positive in the future. These drugs are used to treat ADHD and are taken with stimulants and alone. Atomoxetine is recommended for patients over six years.

ADHD Therapeutics Market - Treatment by Psychotherapy:

• Behaviour Therapy
• Cognitive Behavioral Therapy
• Interpersonal Psychotherapy
• Family Therapy

Based on the psychotherapy treatment type, the behavior therapy segment is the most commonly used method for ADHD treatment. It is an effective treatment that can help children improve their self-esteem, behavior, and self-control. It is primarily helpful with the stimulant medication going on, and we can see a reduction in drug dosage with time.

Interpersonal psychotherapy is a time-limited and focused approach to treating mood disorders. Its popularity is increasing daily and is very effective in treating ADHD.

Family therapy is very effective in treating ADHD, and its popularity is increasing daily.

ADHD Therapeutics Market - Treatment by Education or Training:

• Parent Management Training
• Social Skills Training
• School-Based Interventions

Parent Management Training is the most popular among others. It is incredibly efficient in treating ADHD, and the rising awareness about its effectiveness will further drive its market.

Social skills training by schools and experts is also very effective in treating ADHD. School based intervention methods are also being used more to treat ADHD, and with the rising number of cases, the method will increase quickly.

ADHD Therapeutics Market – By Region:

• North America
• Europe
• Asia Pacific
• Latin America
• Middle East and Africa

Geographically, the North American ADHD therapeutics market commanded a share of 36.0% of the global market in 2022. The growth of the North American market is driven by the growing rate of patients with attention deficit hyperactivity disorder and high healthcare expenditure. It is the reason behind the large revenue pocket of the local market in the U.S. Therefore, the region would hold its leading position in the global attention deficit hyperactivity disorder therapeutics market in the forecast period. 

The Europe ADHD therapeutics market held the second-most position in the global market in 2022, along with emerging technology and digital medicines. The rising healthcare expenditure is one of the notable factors contributing to the growth of the European market.

The Asia Pacific ADHD therapeutics market is growing at a CAGR of 12.3% during the forecast period. The factors responsible for the market's growth are the unmet needs and sizeable patient population, and even the availability of lower-cost drugs for ADHD treatment. Moreover, improving the economy in the region is acting as a key to the success of pushing up the regional market and boosting the healthcare sector. Private organizations and the increased funding from the population are responsible for the regional market's growth. In addition, the explosion of healthcare insurance in many countries like Malaysia, Thailand, and Vietnam is expected to drive the ADHD market in the Asia Pacific. Also, the availability of new treatments and technology affects the growing demand and propels the growth of the regional ADHD therapeutics market.

The Latin American ADHD therapeutics market is estimated to be worth USD 1.53 billion by 2027. On the other hand, the ADHD therapeutics market in the Middle East and Africa is predicted to grow at a CAGR of 9.31% from 2022 to 2027.

KEY MARKET PARTICIPANTS:

Some of the key market players dominating the global ADHD therapeutics market profiled in the report are Shire plc (Ireland), Neos Therapeutics, Inc. (U.S.), Eli Lilly and Company (U.S.), Pfizer Inc. (U.S.), Alcobra Ltd. (Israel), Supernus Pharmaceuticals, Inc. (U.S.), Noven Pharmaceuticals, Inc. (U.S.), Novartis AG (Switzerland), Johnson & Johnson (U.S.) and Curemark, LLC. (U.S.).

RECENT HAPPENINGS IN THIS MARKET:

• In September 2022, Adderall is a stimulative hormone used in the treatment of ADHD (Attention-Deficit Hyperactivity Disorder); the drug is also naturally produced by the Adderall glad placed above the kidney and is generally addressed as (Flight or fight response drug) The overuse of this drug, which according to the article is mentioned to be increased by 10%, increases the chances of worsening mental conditions, promoting the development of depression and anxiety. Furthermore, due to the reason that 85 million people are diagnosed, Americans contributing to 45% of the augmenting prescription of this drug is becoming a matter of concern.
• In May 2022, Qelbree, a viloxazine pill, is now being prescribed to ADHD patients expecting the substitute with stimulating medications that could trigger side effects such as sleeplessness, agitation, and lack of appetite, among others. In addition, the alarming risk for drug abuse propels the need for non-stimulant drugs. The label expansion is the most recent development in the non-stimulant ADHD drug landscape as the medications production of non-stimulant treatment sores new opportunities for market growth are anticipated to improve.
• On MARCH 10, 2023, Cingulate, a Kansas-based Biopharmaceutical company, announced positive results from its new research on the effects of food on their extended-release tablet therapeutics for ADHD, the CTx-1301.